ZA200904353B - In vivo screening models for treatment of alzheimer's disease and other Qpct-related disorders - Google Patents
In vivo screening models for treatment of alzheimer's disease and other Qpct-related disordersInfo
- Publication number
- ZA200904353B ZA200904353B ZA200904353A ZA200904353A ZA200904353B ZA 200904353 B ZA200904353 B ZA 200904353B ZA 200904353 A ZA200904353 A ZA 200904353A ZA 200904353 A ZA200904353 A ZA 200904353A ZA 200904353 B ZA200904353 B ZA 200904353B
- Authority
- ZA
- South Africa
- Prior art keywords
- qpct
- treatment
- alzheimer
- disease
- related disorders
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 238000012750 in vivo screening Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Animal Husbandry (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Biodiversity & Conservation Biology (AREA)
- Psychology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88564907P | 2007-01-19 | 2007-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200904353B true ZA200904353B (en) | 2010-09-29 |
Family
ID=39271322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200904353A ZA200904353B (en) | 2007-01-19 | 2008-01-18 | In vivo screening models for treatment of alzheimer's disease and other Qpct-related disorders |
Country Status (13)
Country | Link |
---|---|
US (1) | US20080200567A1 (es) |
EP (2) | EP2395095A1 (es) |
JP (1) | JP2010516235A (es) |
AT (1) | ATE521711T1 (es) |
AU (1) | AU2008206936B2 (es) |
CA (1) | CA2675192A1 (es) |
DK (1) | DK2121944T3 (es) |
ES (1) | ES2372229T3 (es) |
HR (1) | HRP20110651T1 (es) |
NZ (1) | NZ578513A (es) |
SI (1) | SI2121944T1 (es) |
WO (1) | WO2008087197A1 (es) |
ZA (1) | ZA200904353B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9277737B2 (en) | 2006-09-21 | 2016-03-08 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the QPCTL-gene |
US20120070444A1 (en) | 2007-01-19 | 2012-03-22 | Probiodrug Ag | IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS |
JP5612860B2 (ja) * | 2007-03-09 | 2014-10-22 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのイミダゾ[1,5−a]ピリジン誘導体 |
JP5675341B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体 |
JP5675342B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのシアノグアニジン誘導体 |
ES2473621T3 (es) * | 2007-04-18 | 2014-07-07 | Probiodrug Ag | Derivados de nitrovinil-diamina como inhibidores de glutaminil ciclasa |
WO2008128986A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Urea derivatives as glutaminyl cyclase inhibitors |
DK2142514T3 (da) * | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
DK2142513T3 (da) * | 2007-04-18 | 2014-06-10 | Probiodrug Ag | Nitrovinyl-diamin-derivater som glutaminyl-cyclase-inhibitorer |
US8188094B2 (en) * | 2007-04-20 | 2012-05-29 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2008297070A1 (en) * | 2007-09-12 | 2009-03-19 | Probiodrug Ag | Transgenic mice |
AU2009204864A1 (en) | 2008-01-14 | 2009-07-23 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene |
MX2011001093A (es) * | 2008-07-31 | 2011-03-15 | Probiodrug Ag | Glutaminil ciclasa como un indicador para el diagnostico / pronostico de enfermedades neurodegenerativas. |
US11219696B2 (en) * | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
ES2540467T3 (es) | 2010-08-19 | 2015-07-09 | Probiodrug Ag | Estructura cristalina de glutaminil ciclasa |
WO2012059413A1 (en) | 2010-11-02 | 2012-05-10 | Probiodrug Ag | Crystal structure of isoglutaminyl cyclase |
US20130052203A1 (en) | 2011-08-12 | 2013-02-28 | Probiodrug Ag | In vivo screening models for treatment of qc-related disorders |
EP3769789A1 (en) | 2012-08-01 | 2021-01-27 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
WO2017079547A2 (en) * | 2015-11-04 | 2017-05-11 | The Scripps Research Institute | Compositions and methods for treating cystic fibrosis |
MC200185B1 (fr) | 2016-09-16 | 2017-10-04 | Coronal Audio | Dispositif et procédé de captation et traitement d'un champ acoustique tridimensionnel |
MC200186B1 (fr) | 2016-09-30 | 2017-10-18 | Coronal Encoding | Procédé de conversion, d'encodage stéréophonique, de décodage et de transcodage d'un signal audio tridimensionnel |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
US6948038B2 (en) * | 2001-07-24 | 2005-09-20 | Microsoft Corporation | System and method for backing up and restoring data |
NZ543146A (en) | 2003-05-05 | 2008-09-26 | Probiodrug Ag | Use of effectors of glutaminyl cyclase (QC) activity in combination with inhibitors of DP IV or DP IV-like enzymes for the treatment of conditions that can be treated by modulation of QC-and/or DPIV-activity |
DE202004021723U1 (de) * | 2003-05-05 | 2010-07-15 | Probiodrug Ag | Medizinische Verwendung von Hemmern von Glutaminyl- und Glutamatcyclasen |
DE602004026289D1 (de) * | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
NZ546887A (en) * | 2003-11-03 | 2009-04-30 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
JP4996926B2 (ja) * | 2004-02-05 | 2012-08-08 | プロビオドルグ エージー | グルタミニルシクラーゼの新規の阻害剤 |
GB0704100D0 (en) | 2006-03-17 | 2007-04-11 | Vodafone Plc | Improvements in an ehspa architecture |
CA2663635A1 (en) * | 2006-09-21 | 2008-03-27 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
-
2008
- 2008-01-18 EP EP11178419A patent/EP2395095A1/en not_active Withdrawn
- 2008-01-18 WO PCT/EP2008/050532 patent/WO2008087197A1/en active Application Filing
- 2008-01-18 ZA ZA200904353A patent/ZA200904353B/xx unknown
- 2008-01-18 US US12/016,266 patent/US20080200567A1/en not_active Abandoned
- 2008-01-18 NZ NZ578513A patent/NZ578513A/en not_active IP Right Cessation
- 2008-01-18 AT AT08707977T patent/ATE521711T1/de active
- 2008-01-18 JP JP2009545932A patent/JP2010516235A/ja active Pending
- 2008-01-18 AU AU2008206936A patent/AU2008206936B2/en not_active Ceased
- 2008-01-18 DK DK08707977.8T patent/DK2121944T3/da active
- 2008-01-18 EP EP08707977A patent/EP2121944B1/en not_active Not-in-force
- 2008-01-18 SI SI200830434T patent/SI2121944T1/sl unknown
- 2008-01-18 ES ES08707977T patent/ES2372229T3/es active Active
- 2008-01-18 CA CA002675192A patent/CA2675192A1/en not_active Abandoned
-
2011
- 2011-09-09 HR HR20110651T patent/HRP20110651T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
ES2372229T3 (es) | 2012-01-17 |
EP2121944A1 (en) | 2009-11-25 |
EP2121944B1 (en) | 2011-08-24 |
ATE521711T1 (de) | 2011-09-15 |
DK2121944T3 (da) | 2011-10-31 |
AU2008206936A1 (en) | 2008-07-24 |
AU2008206936B2 (en) | 2013-03-14 |
SI2121944T1 (sl) | 2011-12-30 |
HRP20110651T1 (hr) | 2011-10-31 |
EP2395095A1 (en) | 2011-12-14 |
JP2010516235A (ja) | 2010-05-20 |
WO2008087197A1 (en) | 2008-07-24 |
CA2675192A1 (en) | 2008-07-24 |
US20080200567A1 (en) | 2008-08-21 |
NZ578513A (en) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200904353B (en) | In vivo screening models for treatment of alzheimer's disease and other Qpct-related disorders | |
WO2009034158A3 (en) | Transgenic mice | |
HK1118577A1 (en) | Rnai expression constructs rnai | |
WO2008121199A3 (en) | Transgenic animal models of disease | |
ATE462787T1 (de) | Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington | |
UA101301C2 (ru) | ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ | |
EP1738318A4 (en) | HEALTH INSURANCE PROGRAM ON BONUS BASIS | |
EP1955141A4 (en) | ONLINE MARKETPLACE FOR ANIMAL LEGACY | |
EP1899477A4 (en) | INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS | |
EE200600039A (et) | Transgeenne loommudel patoloogilise ärevuse modelleerimiseks, meetod patoloogilisest ärevusest p?hjustatud haiguste v?i seisundite ravimiseks sobilike ühendite tuvastamiseks ja meetod Wfs1 valgu kasutamiseks sihtmärgina patoloogilise ärevuse vastase | |
ATE502298T1 (de) | Verfahren und materialien zur beurteilung von prostatakrebstherapien | |
MX2010003610A (es) | Marcadores geneticos para ganado astado y sin cuernos, y metodos relacionados. | |
WO2006102370A3 (en) | Functional brain mri mapping as a marker in cns diseases and disorders | |
MX2009006685A (es) | Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos. | |
MX2010002759A (es) | Procedimientos de uso de marcadores geneticos e interacciones epistaticas relacionadas. | |
EP2005174A4 (en) | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES, IN PARTICULAR ALZHEIMER'S DISEASE, AND IMPROVING NORMAL MEMORY | |
ATE511348T1 (de) | Transgenes modell für morbus alzheimer | |
Castillo-Mariqueo et al. | Clasping, ledge-score coordination and early gait impairments as primary behavioural markers of functional impairment in Alzheimer's disease | |
HK1204651A1 (en) | Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof | |
WO2004062627A3 (en) | In vivo screening models for treatment of alzheimer's disease and other neurodegenerative disorders | |
WO2013024043A3 (en) | In vivo screening models for treatment of qc-related disorders | |
EP1811833A4 (en) | NONHUMAN TRANSGENIC MODELS AND ISCHEMIC REPERFUSION INJURY ANIMALS AND USES THEREOF | |
IL185653A (en) | Antibodies that call for the 1-kim salt region | |
WO2007135570A3 (en) | Pink1 deficient animals, screening methods, and related therapeutics | |
EP1483962A3 (en) | Transgenic animal model for Glyt1 function |